Metabolic syndrome and drug discontinuation in schizophrenia

A randomized trial comparing aripiprazole olanzapine and haloperidol

A. Parabiaghi, M. Tettamanti, B. D'Avanzo, A. Barbato, Eugenio Aguglia, Chiara Bufalino, Dario Cannavò, Liliana Gandolfo, Mariano Bassi, Arcadio Erlicher, Germana Agnetti, Giancarlo Breviario, Massimo Casacchia, Rocco Pollice, Paolo Pomero, Antonio Colotto, Samuele Manfrinati, Carlo I. Cattaneo, Giulio Corrivetti, Gaetano Pinto & 31 others Luigi Ferrannini, Maurizio Marcenaro, Marco Vaggi, Lucio Ghio, Werner Natta, Farida Ferrato, Antonio Francomano, Maddalena La Placa, Antonino Mastroeni, Danilo Rigamonti, Christian Groppi, Massimo C. Mauri, Ilaria F. De Gaspari, Mauro Percudani, Rocco Picci, Laura Comino, Elena Paschetta, Rosaria Pioli, Stefano Bignotti, Giovanni Smerieri, Emanuela Ghinaglia, Enrico Visani, Adelia Lucattini, Edgardo Caverzasi, Roberto Colombo, Alice Cervetti, Angela D'Aloise, Vincenzo Fricchione Parise, Vincenzo Florio, Aristotele Hadjichristos, GiSAS study group

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: To determine whether the prescription of aripiprazole, compared with olanzapine and haloperidol, was associated with a lower frequency of metabolic syndrome (MS) and treatment discontinuation at 1 year. Method: Patients were randomly assigned to be treated open-label and according to usual clinical practice with either aripiprazole, olanzapine, or haloperidol and followed up for 1 year. Results: Three hundred out-patients with persistent schizophrenia were recruited in 35 mental health services. The intention-to-treat (ITT) analysis found no significant differences in the rate of MS between aripiprazole (37%), olanzapine (47%), and haloperidol (42%). Treatment discontinuation for any cause was higher for aripiprazole (52%) than for olanzapine (33%; OR, 0.41; P = 0.004), or haloperidol (37%; OR, 0.51; P = 0.030). No significant difference was found between olanzapine and haloperidol. Time to discontinuation for any cause was longer for olanzapine than for aripiprazole (HR, 0.55; P <0.001). No significant differences were found between haloperidol and aripiprazole, or between olanzapine and haloperidol. Conclusion: The prescription of aripiprazole did not significantly reduce the rates of MS, but its treatment retention was worse. Aripiprazole cannot be considered the safest and most effective drug for maintenance treatment of schizophrenia in routine care, although it may have a place in antipsychotic therapy.

Original languageEnglish
Pages (from-to)63-75
Number of pages13
JournalActa Psychiatrica Scandinavica
Volume133
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

olanzapine
Haloperidol
Schizophrenia
Pharmaceutical Preparations
Prescriptions
Therapeutics
Intention to Treat Analysis
Aripiprazole
Mental Health Services
Antipsychotic Agents

Keywords

  • Adverse effects
  • Antipsychotic drugs
  • Clinical trial
  • Effectiveness

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Metabolic syndrome and drug discontinuation in schizophrenia : A randomized trial comparing aripiprazole olanzapine and haloperidol. / Parabiaghi, A.; Tettamanti, M.; D'Avanzo, B.; Barbato, A.; Aguglia, Eugenio; Bufalino, Chiara; Cannavò, Dario; Gandolfo, Liliana; Bassi, Mariano; Erlicher, Arcadio; Agnetti, Germana; Breviario, Giancarlo; Casacchia, Massimo; Pollice, Rocco; Pomero, Paolo; Colotto, Antonio; Manfrinati, Samuele; Cattaneo, Carlo I.; Corrivetti, Giulio; Pinto, Gaetano; Ferrannini, Luigi; Marcenaro, Maurizio; Vaggi, Marco; Ghio, Lucio; Natta, Werner; Ferrato, Farida; Francomano, Antonio; La Placa, Maddalena; Mastroeni, Antonino; Rigamonti, Danilo; Groppi, Christian; Mauri, Massimo C.; De Gaspari, Ilaria F.; Percudani, Mauro; Picci, Rocco; Comino, Laura; Paschetta, Elena; Pioli, Rosaria; Bignotti, Stefano; Smerieri, Giovanni; Ghinaglia, Emanuela; Visani, Enrico; Lucattini, Adelia; Caverzasi, Edgardo; Colombo, Roberto; Cervetti, Alice; D'Aloise, Angela; Parise, Vincenzo Fricchione; Florio, Vincenzo; Hadjichristos, Aristotele; GiSAS study group.

In: Acta Psychiatrica Scandinavica, Vol. 133, No. 1, 01.01.2016, p. 63-75.

Research output: Contribution to journalArticle

Parabiaghi, A, Tettamanti, M, D'Avanzo, B, Barbato, A, Aguglia, E, Bufalino, C, Cannavò, D, Gandolfo, L, Bassi, M, Erlicher, A, Agnetti, G, Breviario, G, Casacchia, M, Pollice, R, Pomero, P, Colotto, A, Manfrinati, S, Cattaneo, CI, Corrivetti, G, Pinto, G, Ferrannini, L, Marcenaro, M, Vaggi, M, Ghio, L, Natta, W, Ferrato, F, Francomano, A, La Placa, M, Mastroeni, A, Rigamonti, D, Groppi, C, Mauri, MC, De Gaspari, IF, Percudani, M, Picci, R, Comino, L, Paschetta, E, Pioli, R, Bignotti, S, Smerieri, G, Ghinaglia, E, Visani, E, Lucattini, A, Caverzasi, E, Colombo, R, Cervetti, A, D'Aloise, A, Parise, VF, Florio, V, Hadjichristos, A & GiSAS study group 2016, 'Metabolic syndrome and drug discontinuation in schizophrenia: A randomized trial comparing aripiprazole olanzapine and haloperidol', Acta Psychiatrica Scandinavica, vol. 133, no. 1, pp. 63-75. https://doi.org/10.1111/acps.12468
Parabiaghi, A. ; Tettamanti, M. ; D'Avanzo, B. ; Barbato, A. ; Aguglia, Eugenio ; Bufalino, Chiara ; Cannavò, Dario ; Gandolfo, Liliana ; Bassi, Mariano ; Erlicher, Arcadio ; Agnetti, Germana ; Breviario, Giancarlo ; Casacchia, Massimo ; Pollice, Rocco ; Pomero, Paolo ; Colotto, Antonio ; Manfrinati, Samuele ; Cattaneo, Carlo I. ; Corrivetti, Giulio ; Pinto, Gaetano ; Ferrannini, Luigi ; Marcenaro, Maurizio ; Vaggi, Marco ; Ghio, Lucio ; Natta, Werner ; Ferrato, Farida ; Francomano, Antonio ; La Placa, Maddalena ; Mastroeni, Antonino ; Rigamonti, Danilo ; Groppi, Christian ; Mauri, Massimo C. ; De Gaspari, Ilaria F. ; Percudani, Mauro ; Picci, Rocco ; Comino, Laura ; Paschetta, Elena ; Pioli, Rosaria ; Bignotti, Stefano ; Smerieri, Giovanni ; Ghinaglia, Emanuela ; Visani, Enrico ; Lucattini, Adelia ; Caverzasi, Edgardo ; Colombo, Roberto ; Cervetti, Alice ; D'Aloise, Angela ; Parise, Vincenzo Fricchione ; Florio, Vincenzo ; Hadjichristos, Aristotele ; GiSAS study group. / Metabolic syndrome and drug discontinuation in schizophrenia : A randomized trial comparing aripiprazole olanzapine and haloperidol. In: Acta Psychiatrica Scandinavica. 2016 ; Vol. 133, No. 1. pp. 63-75.
@article{5bf602a77d1849e984633eb03d7c4e11,
title = "Metabolic syndrome and drug discontinuation in schizophrenia: A randomized trial comparing aripiprazole olanzapine and haloperidol",
abstract = "Objective: To determine whether the prescription of aripiprazole, compared with olanzapine and haloperidol, was associated with a lower frequency of metabolic syndrome (MS) and treatment discontinuation at 1 year. Method: Patients were randomly assigned to be treated open-label and according to usual clinical practice with either aripiprazole, olanzapine, or haloperidol and followed up for 1 year. Results: Three hundred out-patients with persistent schizophrenia were recruited in 35 mental health services. The intention-to-treat (ITT) analysis found no significant differences in the rate of MS between aripiprazole (37{\%}), olanzapine (47{\%}), and haloperidol (42{\%}). Treatment discontinuation for any cause was higher for aripiprazole (52{\%}) than for olanzapine (33{\%}; OR, 0.41; P = 0.004), or haloperidol (37{\%}; OR, 0.51; P = 0.030). No significant difference was found between olanzapine and haloperidol. Time to discontinuation for any cause was longer for olanzapine than for aripiprazole (HR, 0.55; P <0.001). No significant differences were found between haloperidol and aripiprazole, or between olanzapine and haloperidol. Conclusion: The prescription of aripiprazole did not significantly reduce the rates of MS, but its treatment retention was worse. Aripiprazole cannot be considered the safest and most effective drug for maintenance treatment of schizophrenia in routine care, although it may have a place in antipsychotic therapy.",
keywords = "Adverse effects, Antipsychotic drugs, Clinical trial, Effectiveness",
author = "A. Parabiaghi and M. Tettamanti and B. D'Avanzo and A. Barbato and Eugenio Aguglia and Chiara Bufalino and Dario Cannav{\`o} and Liliana Gandolfo and Mariano Bassi and Arcadio Erlicher and Germana Agnetti and Giancarlo Breviario and Massimo Casacchia and Rocco Pollice and Paolo Pomero and Antonio Colotto and Samuele Manfrinati and Cattaneo, {Carlo I.} and Giulio Corrivetti and Gaetano Pinto and Luigi Ferrannini and Maurizio Marcenaro and Marco Vaggi and Lucio Ghio and Werner Natta and Farida Ferrato and Antonio Francomano and {La Placa}, Maddalena and Antonino Mastroeni and Danilo Rigamonti and Christian Groppi and Mauri, {Massimo C.} and {De Gaspari}, {Ilaria F.} and Mauro Percudani and Rocco Picci and Laura Comino and Elena Paschetta and Rosaria Pioli and Stefano Bignotti and Giovanni Smerieri and Emanuela Ghinaglia and Enrico Visani and Adelia Lucattini and Edgardo Caverzasi and Roberto Colombo and Alice Cervetti and Angela D'Aloise and Parise, {Vincenzo Fricchione} and Vincenzo Florio and Aristotele Hadjichristos and {GiSAS study group}",
year = "2016",
month = "1",
day = "1",
doi = "10.1111/acps.12468",
language = "English",
volume = "133",
pages = "63--75",
journal = "Acta Psychiatrica Scandinavica",
issn = "0001-690X",
publisher = "wiley",
number = "1",

}

TY - JOUR

T1 - Metabolic syndrome and drug discontinuation in schizophrenia

T2 - A randomized trial comparing aripiprazole olanzapine and haloperidol

AU - Parabiaghi, A.

AU - Tettamanti, M.

AU - D'Avanzo, B.

AU - Barbato, A.

AU - Aguglia, Eugenio

AU - Bufalino, Chiara

AU - Cannavò, Dario

AU - Gandolfo, Liliana

AU - Bassi, Mariano

AU - Erlicher, Arcadio

AU - Agnetti, Germana

AU - Breviario, Giancarlo

AU - Casacchia, Massimo

AU - Pollice, Rocco

AU - Pomero, Paolo

AU - Colotto, Antonio

AU - Manfrinati, Samuele

AU - Cattaneo, Carlo I.

AU - Corrivetti, Giulio

AU - Pinto, Gaetano

AU - Ferrannini, Luigi

AU - Marcenaro, Maurizio

AU - Vaggi, Marco

AU - Ghio, Lucio

AU - Natta, Werner

AU - Ferrato, Farida

AU - Francomano, Antonio

AU - La Placa, Maddalena

AU - Mastroeni, Antonino

AU - Rigamonti, Danilo

AU - Groppi, Christian

AU - Mauri, Massimo C.

AU - De Gaspari, Ilaria F.

AU - Percudani, Mauro

AU - Picci, Rocco

AU - Comino, Laura

AU - Paschetta, Elena

AU - Pioli, Rosaria

AU - Bignotti, Stefano

AU - Smerieri, Giovanni

AU - Ghinaglia, Emanuela

AU - Visani, Enrico

AU - Lucattini, Adelia

AU - Caverzasi, Edgardo

AU - Colombo, Roberto

AU - Cervetti, Alice

AU - D'Aloise, Angela

AU - Parise, Vincenzo Fricchione

AU - Florio, Vincenzo

AU - Hadjichristos, Aristotele

AU - GiSAS study group

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objective: To determine whether the prescription of aripiprazole, compared with olanzapine and haloperidol, was associated with a lower frequency of metabolic syndrome (MS) and treatment discontinuation at 1 year. Method: Patients were randomly assigned to be treated open-label and according to usual clinical practice with either aripiprazole, olanzapine, or haloperidol and followed up for 1 year. Results: Three hundred out-patients with persistent schizophrenia were recruited in 35 mental health services. The intention-to-treat (ITT) analysis found no significant differences in the rate of MS between aripiprazole (37%), olanzapine (47%), and haloperidol (42%). Treatment discontinuation for any cause was higher for aripiprazole (52%) than for olanzapine (33%; OR, 0.41; P = 0.004), or haloperidol (37%; OR, 0.51; P = 0.030). No significant difference was found between olanzapine and haloperidol. Time to discontinuation for any cause was longer for olanzapine than for aripiprazole (HR, 0.55; P <0.001). No significant differences were found between haloperidol and aripiprazole, or between olanzapine and haloperidol. Conclusion: The prescription of aripiprazole did not significantly reduce the rates of MS, but its treatment retention was worse. Aripiprazole cannot be considered the safest and most effective drug for maintenance treatment of schizophrenia in routine care, although it may have a place in antipsychotic therapy.

AB - Objective: To determine whether the prescription of aripiprazole, compared with olanzapine and haloperidol, was associated with a lower frequency of metabolic syndrome (MS) and treatment discontinuation at 1 year. Method: Patients were randomly assigned to be treated open-label and according to usual clinical practice with either aripiprazole, olanzapine, or haloperidol and followed up for 1 year. Results: Three hundred out-patients with persistent schizophrenia were recruited in 35 mental health services. The intention-to-treat (ITT) analysis found no significant differences in the rate of MS between aripiprazole (37%), olanzapine (47%), and haloperidol (42%). Treatment discontinuation for any cause was higher for aripiprazole (52%) than for olanzapine (33%; OR, 0.41; P = 0.004), or haloperidol (37%; OR, 0.51; P = 0.030). No significant difference was found between olanzapine and haloperidol. Time to discontinuation for any cause was longer for olanzapine than for aripiprazole (HR, 0.55; P <0.001). No significant differences were found between haloperidol and aripiprazole, or between olanzapine and haloperidol. Conclusion: The prescription of aripiprazole did not significantly reduce the rates of MS, but its treatment retention was worse. Aripiprazole cannot be considered the safest and most effective drug for maintenance treatment of schizophrenia in routine care, although it may have a place in antipsychotic therapy.

KW - Adverse effects

KW - Antipsychotic drugs

KW - Clinical trial

KW - Effectiveness

UR - http://www.scopus.com/inward/record.url?scp=84954388684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954388684&partnerID=8YFLogxK

U2 - 10.1111/acps.12468

DO - 10.1111/acps.12468

M3 - Article

VL - 133

SP - 63

EP - 75

JO - Acta Psychiatrica Scandinavica

JF - Acta Psychiatrica Scandinavica

SN - 0001-690X

IS - 1

ER -